stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Symbol Search Browse Symbols My Charts Menu
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of Inc. / TFC Commodity Charts

Monoclonal Antibodies (mAbs) Market Size is Expected to Exhibit 148.9 billion USD by 2026

Nov 08, 2019 (AmericaNewsHour) --
Market Study Report Provides A Detailed Overview Of Monoclonal Antibodies (mAbs) Market With Respect To The Pivotal Drivers Influencing The Revenue Graph Of This Business Sphere. The Current Trends Of Monoclonal Antibodies (mAbs) Market In Conjunction With The Geographical Landscape, Demand Spectrum, Remuneration Scale, And Growth Graph Of This Vertical Have Also Been Included In This Report.

According to a new study the worldwide monoclonal antibodies market is anticipated to reach over USD 148.9 billion by 2026.

Request a sample of this premium report titled at:

In 2017, by indication, the cancer segment dominated the global market in terms of revenue; wherein fully-human monoclonal antibodies held a major share of the market. In terms of geography, North America accounted for the majority share in the global monoclonal antibodies market.

Monoclonal antibodies constitute a major share of the pharmaceutical market with several monoclonal antibodies still in the pipeline. With over 30 monoclonal antibodies approved for use by regulatory authorities, many monoclonal antibodies are in the pipeline at the pre-clinical stage and various stages of clinical trials. Furthermore, availability of advanced technology for monoclonal antibodies production has egged on many other market players to develop their own pipelines. Also, in the last few years the patents of many monoclonal antibodies have expired thereby encouraging other pharmaceutical companies to undertake production of monoclonal antibodies.

The monoclonal antibodies (mAbs) market is mainly driven by an active pipeline, wherein many monoclonal antibodies are at the different stages of drug development. In addition, increased in research and development, favorable government policies and rising prevalence of cancer and other chronic diseases supplement the market growth. The other factors that augment that market growth include the increasing the demand for personalized medicine and rising awareness among medical professional and patients about the latest medical therapies. Moreover, emerging targets such as central nervous system disorders, price correction and new delivery strategies for monoclonal antibodies provide opportunities for market growth in the near future.

Personalized medicine is being redefined by monoclonal antibodies that are the cutting-edge form of immunotherapy. The surge in the demand for personalized medicine plays a crucial role in boosting the monoclonal antibodies market by giving an impetus to the development of personalized drug targets as every patient responds differently to different treatment regimens. Moreover, other factors such as specificity, homogeneity and relatively fewer adverse events that entail usage of personalized medicine contribute to significant market growth.

The widespread and rapidly increasing prevalence of cancer and other chronic diseases have resulted in the soaring demand of biological medicines, thereby augmenting the growth of monoclonal antibodies. Furthermore several other monoclonal antibodies used in treatment of deadly infections such as HIV/AIDS, Ebola and Zika viral disease are in various phases of clinical trials. Also, high spending power of patients in developed countries, increasing disposable incomes in developing countries and better healthcare facilities further facilitate market growth. Going forward, increasing awareness about the latest medical therapies among medical professional and patients, and increasing utilization of monoclonal antibodies in treatment regimens is anticipated to propel the market growth.

There has been an increase in the research and development activities in the field of monoclonal antibodies. Several biomedical and technological advances in genetic engineering and next generation genome sequencing have fuelled the growth of the monoclonal antibody market. Also, multiple new targets have been identified during preclinical research, which has led to the development and production of newer monoclonal antibodies by using various cytotechnological methodologies. In addition to this, favorable government initiatives to enable cost-effective production of monoclonal antibodies would give impetus to the monoclonal antibodies market growth. Also, pre-defined guidelines by regulatory bodies would ensure the safe, effective and high quality manufacturing of monoclonal antibodies Recently, the European Commission approved the first biosimilar mAb Celltrion’s Truxima (biosimilar rituximab), thereby boding well for its potential approval in the U.S.

Based on indication, the global monoclonal antibodies market is segmented in to cancer, inflammation, cardiovascular diseases, transplant rejection, respiratory and infectious diseases. The cancer segment is expected to lead the market during the forecast period owing to rapidly expanding patient pool, awareness about monoclonal antibodies among physicians and patients, improving medical facilities, high spending power in developed countries and increasing disposable incomes in developing countries.

The leading companies operating in this industry include Pfizer, Inc., GlaxoSmithKline PLC, Novartis AG, Merck & Co., Inc., Eli Lily & Co., AstraZeneca, Amgen, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Hoffmann-La Roche Ltd., and Novo Nordisk A/S. The market players have adopted various strategies such as novel product development, new product release, and venture capital investments among others to establish a foothold in the market and increase their customer base.

Request a discount on standard prices of this premium report titled at:

Table of Contents:

1.         Overview and Scope

1.1.      Research goal & scope

1.2.      Research assumptions

1.3.      Research methodology

1.3.1.   Primary data sources

1.3.2.   Secondary data sources

1.4.      Key take-away

1.5.      Stakeholders

2.         Executive Summary

2.1.      Market definition

2.2.      Market segmentation

3.         Monoclonal Antibodies Market Insights

3.1.      Monoclonal Antibodies ? Industry snapshot

3.2.      Monoclonal Antibodies – Ecosystem analysis

3.3.      Monoclonal Antibodies Market Dynamics

3.3.1.   Monoclonal Antibodies ? Market Forces            Monoclonal Antibodies Market Driver Analysis            Monoclonal Antibodies Market Restraint/Challenges analysis            Monoclonal Antibodies Market Opportunity Analysis

3.3.2.   Industry analysis – Porter’s five forces            Bargaining power of supplier            Bargaining power of buyer            Threat of substitute            Threat of new entrant            Degree of competition

3.3.3.   Monoclonal Antibodies Market PEST Analysis, 2017

3.3.4.   Monoclonal Antibodies Market Value Chain Analysis

3.3.5.   Monoclonal Antibodies Industry Trends

3.3.6.   Competitive Ranking Analysis

4.         Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Product Type

4.1.      Key Findings

4.2.      Fully Human

4.3.      Murine

4.4.      Chimeric

4.5.      Humanized

5.         Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Production System

5.1.      Key Findings

5.2.      Mammalian Cell Culture

5.3.      Microbial Fermentation

6.         Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Indication

6.1.      Key Findings

6.2.      Cancer

6.3.      Inflammation

6.4.      Cardiovascular diseases

6.5.      Transplant Rejection

6.6.      Respiratory

6.7.      Infectious diseases

7.         Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Technology Platforms

7.1.      Key Findings

7.2.      Transgenic-Mouse

7.3.      Antibody Drug Conjugate

7.4.      Phage-Display

8.         Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Target Mechanism of Action

8.1.      Key Findings

8.2.      CGRP

8.3.      HER2

8.4.      CTLA4

8.5.      TNF alpha

8.6.      EGFR

8.7.      VEGF

8.8.      Anti CD

8.9.      Anti-IL

8.10.    IgGs, PD-1/PD-L1

9.         Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Care Delivery Setting

9.1.      Key Findings

9.2.      Primary

9.3.      Specialty Care

10.       Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Route of Administration

10.1.    Key Findings

10.2.    Subcutaneous

10.3.    Intravenous

11.       Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Drug Types

11.1.    Key Findings

11.2.    Branded Biologics

11.3.    Biosimilars

12.       Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Region

12.1.    Key Findings

12.2.    North America

12.2.1. U.S.

12.2.2. Canada

12.3.    Europe

12.3.1. UK

12.3.2. Germany

12.3.3. Rest of Europe

Questions? Get them answered via before taking a buying decision on this premium report titled Global Monoclonal Antibodies (mAbs) Market

About Us: allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:

Market Study Report LLC
4 North Main Street,

Selbyville, Delaware 19975


Phone: 1-302-273-0910

US Toll Free: 1-866-764-2150




The post Monoclonal Antibodies (mAbs) Market Size is Expected to Exhibit 148.9 billion USD by 2026 appeared first on America News Hour.

Copyright © 2019. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.